Anzeige
Mehr »
Lynx Broker
Login
Dienstag, 22.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien
Folgen Sie der Spur! Kein Unternehmen hat bessere Karten! Und jetzt auch noch das…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AH3F ISIN: DK0060732477 Ticker-Symbol: ONQ 
Berlin
22.10.19
18:46 Uhr
0,209 Euro
-0,001
-0,48 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ONCOLOGY VENTURE A/S Chart 1 Jahr
5-Tage-Chart
ONCOLOGY VENTURE A/S 5-Tage-Chart

Aktuelle News zur ONCOLOGY VENTURE Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoOncology Venture A/S: The Board of Oncology Venture resolves to conduct a rights issue of new shares, and publishes ...-
ONCOLOGY VENTURE Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten!
15.10.Oncology Venture A/S: Minutes of Extraordinary General Meeting-
23.09.Oncology Venture A/S: Oncology Venture presents positive data at ESMO on DRP as a response predictor for 5-FU ...-
13.09.Oncology Venture - New CEO as company moves toward late stage155Oncology Venture announced on 4 September 2019 that it has appointed a new CEO, Steve Carchedi, former senior executive of J&J and Mallinckrodt. This comes at a critical juncture for the company as...
► Artikel lesen
04.09.Oncology Venture A/S: Oncology Venture provides further information on the terms for a proposed rights issue-
30.08.Oncology Venture A/S: Oncology Venture publishes Interim Report for the period January - June 2019-
15.08.Oncology Venture A/S: FDA grants IDE approval to use Oncology Venture's LiPlaCis DRP for patient selection in ...1
22.07.Nasdaq Stockholm AB: New equity right for trading, Oncology Venture TO 1 (278/19)69At the request of Oncology Venture A/S, equity rights will be traded on First North as from July 24, 2019. Security name: Oncology Venture TO 1 ------------------------------------- Short name: ...
► Artikel lesen
21.07.Oncology Venture A/S: Oncology Venture - First day of trading in investor warrants-
28.06.Oncology Venture A/S: New company takes over Certified Advisor role to OV-
24.06.Oncology Venture A/S: Oncology Venture gets European patent on its AI powered method to find patients who will ...-
13.06.Oncology Venture A/S: Oncology Venture provides financial details regarding its recent acquisition of additional ...-
13.06.Oncology Venture A/S: Oncology Venture increases its ownership in dovitinib1
12.06.Oncology Venture - Multiple studies moving forward27Oncology Venture (OV) continues to make progress developing its oncology assets and the drug response predictor (DRP) companion diagnostic. The company has licensed six assets to date with prior clinical...
► Artikel lesen
04.06.Oncology Venture A/S: OV's method can predict if neoadjuvant treatment with doxorubicin in breast cancer will be successful, data published in ASCO journal32Investor News Hoersholm, Denmark and Cambridge, MA, US, June 4, 2019. - Oncology Venture A/S ("OV" or "the Company") today announced that an e-abstract has been published in Journal of Clinical...
► Artikel lesen
03.06.Oncology Venture A/S: Oncology Venture receives response from the FDA to the IND-application and proposed pivotal ...-
03.06.Nasdaq Stockholm AB: Last day of trading in paid subscription units (BTU) of Oncology Venture A/S (203(19)37Trading in Oncology Venture A/S paid subscription units is to cease. The last trading day is June 4, 2019. Short name: OV BTU --------------------------- ISIN code: SE0012507325 --------------------------- Orderbook...
► Artikel lesen
31.05.Oncology Venture A/S: Oncology Venture publishes Q1 report for 2019-
28.05.Oncology Venture A/S: Oncology Venture - New date for registration of current rights issue-
16.05.Oncology Venture A/S: Oncology Venture has successfully executed capital increase with a value in excess of SEK ...-
Seite:  Weiter >>
39 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1